Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial

Documenti analoghi

• The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
  di: Elias John Elenjickal, et al.
  Pubblicazione: (2026)
• Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof‐of‐concept results from the DECIDE ‐ CV clinical programme
  di: Pedro Marques, et al.
  Pubblicazione: (2024)
• Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial
  di: Navdeep Tangri, et al.
  Pubblicazione: (2024)
• An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes
  di: Angela X. Chen, et al.
  Pubblicazione: (2024)
• Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial
  di: Kathryn Cardoza, et al.
  Pubblicazione: (2024)